The East Asia Bioprocessing Tracker
Overview
Explore insightful data coverage on more than 600 facilities, with information on different manufacturing related parameters of Biopharma and CMO/CDMOs in the East Asia, in easily accessible and understandable formats.
The data is covered across several parameters to provide real-time insights into bioprocessing industry such as the locations of the biologics facilities, production capacity of Biopharma and CMOs, upstream and downstream processing capabilities, adoption of bioprocessing equipment and technologies and exclusive information on company’s future plans and investment. Some of the key companies included in this tracker are Samsung Biologics, Lonza, Beigene, Patheon, ExoCoBio, Bioworkshops and Biocina.
The tracker is underpinned by user-friendly visuals to allow users to filter through data by country, company, product type, scale of operation/phases of development, manufacturing capabilities.
Key Parameters
- bioprocessing facility name
- in-house manufacturing capabilities
- product types and sub-products
- bioprocessing capabilities & processes
- the scale of operation or phases of development
- plant capacity & batch size
- facility size
- current & completed projects of CMOs
- facility name
- location
- establishment year
- facility size & capacity
- process technology
- bioreactor type
- technology/service providers
- ongoing projects/pipeline
- annual production
- batch size
- bioprocessing equipment
- bioreactors
- expression system
- upstream technology/ services
- downstream technology/services
- facility operation technology/services
- drug product technology/services
- regulatory approval
- investments
- future expansion plans
- partnerships & collaborations and other parameters
Regions Coverage
China, Japan, South Korea, Hong Kong and Taiwan
Product Types Covered
Immunotherapeutic
Antibody Therapeutics
Cell Therapy
Protein Therapeutics
Gene Therapy
Vaccines
Blood & Plasma
How This Tracker Will Benefit?
It has over 600 biopharma and CMO/CDMO facilities data from East Asian countries. We ensure delivery of highly-qualified research as we tap into our database of 62000+ life science professionals curated over a decade.
The tracker provides an in-depth overview of the upcoming competition in the East Asia Bioprocessing market. Through this tracker IMAPAC aims to assist organizations to keep track of their competitors, identify any opportunities for collaboration or investments for development or manufacturing of large molecules in the East Asia region, aiding in key strategic decisions for biopharma business industry.
Data Methodology
The data in this tracker is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, survey polls, company websites, press releases, publicly available information, regulatory database and many more.
We have a database of key decision makers from the biopharma companies across the region. We host industry surveys with bioprocessing leaders of CMOs and Biopharma, and host primary interviews with Heads of Manufacturing, R&D, Process Development Heads and multiple stakeholders in the companies to gather data as well as validate that data using our primary research analysts.
Throughout the year, we keep in touch with the KOLs through telephonic Conversation, with Q&A sessions with high profile biopharma professionals, for example CSO/CTO profiles. Apart from telephonic conversations, we send a list of questions which these experts fill in detail and send back to us.
We have dedicated analysts who gather data. The data included in the tracker is validated through primary research (interviews, phone calls) with stakeholders which is then validated by IMAPAC’s research analysts to ensure the accuracy of the data.
Key Questions Answered
- How many bioprocessing facilities are operating in East Asia?
- Where are bioprocessing facilities set up across East Asia?
- Which companies have in-house manufacturing capabilities in East Asia?
- Which biologics are manufactured in each facility in East Asia?
- Which upstream and downstream capabilities are offered by the company?
- What is the scale of upstream manufacturing capacity of each facility?
- Which mode of manufacturing process is followed in each biomanufacturing facility?
- Which bioprocessing equipment and brands are used in biomanufacturing?
- Who is the current bioprocessing technology or service providers of the biopharma, big pharma and CMOs?
- What kind of bioreactors or expression systems are adopted in the bioprocessing?
- What are the current projects of biopharma, big pharma and CMOs in bioprocessing engagement?
- What is the current focus of organizations in terms of cost saving involved in bioprocessing?
- In which phases of development does each organization currently have biopharmaceutical products?
- How many batches are commercially produced in each facility and information into past 1 year production batches?
- What are the components of plant design and challenges faced in plant designing?
- What is the capacity of each manufacturing plant in litre?
- How much investment is made in each facility?
- What are the future plans of Biopharma and CMOs in terms of facility expansion?
Data Sample
Pick the right plan!
From evolving customer expectations and emerging technologies to more nimble companies entering industries, businesses today are more at risk for disruption than ever before.
Silver
$4000
- Access upto 3 months
- Single user
- Quarterly updates
- 3 hours dedicated analyst time for one time use
Gold
$6000
- Access upto 6 months
- Single user
- Quarterly updates
- 3 hours dedicated analyst time for 3 months
Premium
$12,000
- Access for 1 year
- Single Users
- Monthly update's
- 3 hours dedicated analyst time each month for custom research
